Laurus Labs and its partner Aspen Pharmacare, South Africa’s leading pharmaceutical company, have launched a new HIV drug with the triple combination of Tenofovir Disoproxil Fumarate, Lamivudine and Dolutegravir (TLD) in South Africa on November 26, 2018.
As part of the partnership, Aspen launched the product in South Africa for the private market and Laurus Labs will supply the API, from its manufacturing facility located in Jawaharlal Nehru Pharma city, Visakhapatnam, India. This state-of-the-art facility is approved by USFDA.
Earlier, Aspen Pharma received approvals for the dossier where Aspen Port Elizabeth and Laurus Labs Visakhapatnam are registered as manufacturing facilities, from the South African Health Products Regulatory Authority (SAHPRA).
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
